Search Results (2)

This study aimed to analyze the relationship between deans and directors of Korean universities on the organizational commitment of university professors, and the mediating effects of organizational culture and organizational trust. A survey was conducted with full-time professors at 20 universities; 387 responses were analyzed. Structural equation modeling was performed using a two-step approach to achieve the research purpose, and the mediating effects were tested using phantom variables. The analysis revealed that the authentic leadership of deans and directors significantly and positively affected organizational trust, culture, and commitment, with trust being a more important mediator than culture. This study is significant in that most previous studies on university leadership have focused on the university president, the top-level policymaker, and used measurement tools designed for business organizations. Conversely, this study focused on deans and directors, the middle managers at universities, and adapted existing diagnostic tools for universities in Korea with horizontal organizational structures based on academic experience. In Korea, there is currently an emphasis on university reform, evaluation, and financial support. Thus, the importance of deans and directors as the key administrative workforce and enablers in creating a healthy organizational culture is in the spotlight The results suggest the urgent necessity for investment in leadership training for these positions. Full article

O. Harold Warwick graduated in medicine from McGill University as a gold medalist and Rhodes Scholar in 1940. After World War II, he started postgraduate training in Montreal, and in 1946, he began studying the newly described drug treatment of cancer in London, England. There he carried out the first study of nitrogen mustard in a group of adult patients with a non-hematologic solid tumour, lung cancer. After a brief period of practice in Montreal, he moved in 1948 to Toronto, where he became executive director of the Canadian Cancer Society and the National Cancer Institute of Canada. Simultaneously, he joined the staff of Toronto General Hospital and its Radiotherapy Institute, where he became the first physician–oncologist to provide medical care and administer anticancer drugs in a Canadian cancer centre. In 1958, the new Princess Margaret Hospital opened in Toronto; Warwick became its first chief physician, responsible for clinical drug trials. Here he carried out his best known clinical study—the use of vinblastine sulphate in patients with Hodgkin lymphoma. From 1961 to 1971, he served as dean and then vice-president Health Sciences at the University of Western Ontario. He returned to the practice of medical oncology from 1972 to 1980 at the London Cancer Clinic, after which he had a long and productive retirement. He died in October 2009. Although the specialty was not named until the latter years of his career, Harold Warwick satisfied all the criteria for and was undoubtedly Canada’s first medical oncologist. Full article